8-K
filed November 10, 2022, 6:59 PM ET
ticker REVB
CIK 0001810560
earnings
confidence high
sentiment neutral
materiality 0.50
Revelation Biosciences Q3 2022 net loss $1.2M; cash $6.2M, expects runway through June 2023
REVELATION BIOSCIENCES, INC.
2022-Q3 EPS reported
-$0.57
- Net loss Q3 2022 $1.2M ($0.06/share) vs $3.0M ($0.48/share) in Q3 2021.
- Cash $6.2M at Sep 30, 2022, up from $1.3M at Dec 31, 2021; expects to fund ops through June 2023.
- Completed a $5.0M public offering.
- Licensed Vanderbilt IP for REVTx-100; positive preclinical data for REVTx-300 in acute kidney injury.
- Anticipates starting Phase 1a clinical study for REVTx-100 and REVTx-300.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
REVELATION BIOSCIENCES, INC. reported the nine months ended September 30, 2022 results: net income $9.6 million, EPS $0.57 per share.
- Period
- the nine months ended September 30, 2022
- Net income
- $9.6 million
- EPS
- $0.57 per share
- Result
- reported results
Exact text from the filing
Revelation’s net loss for the three and nine months ended September 30, 2022 was $1.2 million and $9.6 million, or $0.06 per share and $0.57 per share, respectively
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
REVELATION BIOSCIENCES, INC. reported the three months ended September 30, 2022 results: net income $1.2 million, EPS $0.06 per share.
- Period
- the three months ended September 30, 2022
- Net income
- $1.2 million
- EPS
- $0.06 per share
- Result
- reported results
Exact text from the filing
Revelation’s net loss for the three and nine months ended September 30, 2022 was $1.2 million and $9.6 million, or $0.06 per share and $0.57 per share, respectively
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.